Compare IFF & PODD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IFF | PODD |
|---|---|---|
| Founded | 1833 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Medical/Dental Instruments |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 19.6B | 22.1B |
| IPO Year | N/A | 2007 |
| Metric | IFF | PODD |
|---|---|---|
| Price | $65.82 | $291.54 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 15 | 19 |
| Target Price | $85.15 | ★ $366.58 |
| AVG Volume (30 Days) | ★ 2.5M | 805.5K |
| Earning Date | 11-04-2025 | 11-06-2025 |
| Dividend Yield | ★ 2.43% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 3.45 |
| Revenue | ★ $11,072,000,000.00 | $2,521,800,000.00 |
| Revenue This Year | N/A | $32.55 |
| Revenue Next Year | N/A | $20.39 |
| P/E Ratio | ★ N/A | $83.93 |
| Revenue Growth | N/A | ★ 27.11 |
| 52 Week Low | $59.14 | $230.05 |
| 52 Week High | $88.09 | $354.88 |
| Indicator | IFF | PODD |
|---|---|---|
| Relative Strength Index (RSI) | 51.38 | 38.05 |
| Support Level | $62.06 | $287.52 |
| Resistance Level | $66.52 | $299.22 |
| Average True Range (ATR) | 1.59 | 8.42 |
| MACD | -0.18 | -1.25 |
| Stochastic Oscillator | 50.50 | 13.46 |
International Flavors & Fragrances is the largest specialty ingredients producer globally. It sells ingredients for the food, beverage, health, household goods, personal care, and pharmaceutical industries. The company makes proprietary formulations, partnering with customers to deliver custom solutions. Through its taste and scent segments, which each generate around 25% of profits, IFF is a leading flavor and fragrances producer. The health and biosciences business, which generates 30% of profits, is a global leader in probiotics and enzymes. The remaining profits come from the food ingredients business, which sells texturants, plant-based proteins, and other ingredients.
Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the US Food and Drug Administration in 2005, approximately 500,000 insulin-dependent diabetic patients are using it worldwide.